Cargando…

Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma

BACKGROUND: A substantial body of literature has accumulated during the past 20 years showing the plasma concentrations of 5-fluorouracil (5-FU) to correlate with clinical response and/or toxicity in colorectal cancer, and head and neck cancer, but little information is available concerning effects...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuwahara, Akiko, Yamamori, Motohiro, Kadoyama, Kaori, Nishiguchi, Kohshi, Nakamura, Tsutomu, Miki, Ikuya, Tamura, Takao, Okuno, Tatsuya, Omatsu, Hideaki, Sakaeda, Toshiyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199256/ https://www.ncbi.nlm.nih.gov/pubmed/21970688 http://dx.doi.org/10.1186/1756-9966-30-94

Ejemplares similares

Effects of Bolus Injection of 5-Fluorouracil on Steady-State Plasma Concentrations of 5-Fluorouracil in Japanese Patients with Advanced Colorectal Cancer
por: Tamura, Takao, et al.
Publicado: (2011)

VEGF -634C/G Genotype is Predictive of Long-term Survival after Treatment with a Definitive 5-Fluorouracil/cisplatin-based Chemoradiotherapy in Japanese Patients with Esophageal Squamous Cell Carcinoma
por: Tamura, Takao, et al.
Publicado: (2012)

Genetic Polymorphisms in SLC23A2 as Predictive Biomarkers of Severe Acute Toxicities after Treatment with a Definitive 5-Fluorouracil/Cisplatin-Based Chemoradiotherapy in Japanese Patients with Esophageal Squamous Cell Carcinoma
por: Minegaki, Tetsuya, et al.
Publicado: (2014)

Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma
por: Kuwahara, Akiko, et al.
Publicado: (2009)

Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma
por: Kuwahara, Akiko, et al.
Publicado: (2010)

TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma
por: Kuwahara, Akiko, et al.
Publicado: (2010)

TNF-α -857C>T Genotype is Predictive of Clinical Response after Treatment with Definitive 5-Fluorouracil/cisplatin-based Chemoradiotherapy in Japanese Patients with Esophageal Squamous Cell Carcinoma
por: Omatsu, Hideaki, et al.
Publicado: (2013)

THRB Genetic Polymorphisms Can Predict Severe Myelotoxicity after Definitive Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma
por: Miki, Ikuya, et al.
Publicado: (2012)

Adverse Event Profiles of 5-Fluorouracil and Capecitabine: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
por: Kadoyama, Kaori, et al.
Publicado: (2011)

Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS
por: Kadoyama, Kaori, et al.
Publicado: (2011)

Antipsychotics-Associated Serious Adverse Events in Children: An Analysis of the FAERS Database
por: Kimura, Goji, et al.
Publicado: (2015)

Lower Body Mass Index is a Risk Factor for In-Hospital Mortality of Elderly Japanese Patients Treated with Ampicillin/sulbactam
por: Miura, Makoto, et al.
Publicado: (2016)

Aspirin- and Clopidogrel-associated Bleeding Complications: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS
por: Tamura, Takao, et al.
Publicado: (2012)

Omeprazole- and Esomeprazole-associated Hypomagnesaemia: Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Tamura, Takao, et al.
Publicado: (2012)

Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2013)

Factors affecting the sensitivity of human-derived esophageal carcinoma cell lines to 5-fluorouracil and cisplatin
por: MINEGAKI, TETSUYA, et al.
Publicado: (2013)

Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Concurrent Chemoradiotherapy with Docetaxel, Cisplatin, and 5-fluorouracil Improves Survival of Patients with Advanced Esophageal Cancer Compared with Conventional Concurrent Chemoradiotherapy with Cisplatin and 5-fluorouracil
por: Tamaki, Yukihisa, et al.
Publicado: (2018)

Commonality of Drug-associated Adverse Events Detected by 4 Commonly Used Data Mining Algorithms
por: Sakaeda, Toshiyuki, et al.
Publicado: (2014)

Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer
por: Kim, Yeon-Joo, et al.
Publicado: (2013)

Cisplatin/5-Fluorouracil (5-FU) Versus Carboplatin/Paclitaxel Chemoradiotherapy as Definitive or Pre-Operative Treatment of Esophageal Cancer
por: Steber, Cole, et al.
Publicado: (2021)

Effects of the Plasma Concentration of 5‐Fluorouracil and the Duration of Continuous Venous Infusion of 5‐Fluorouracil with an Inhibitor of 5‐Fluorouracil Degradation on Yoshida Sarcomas in Rats
por: Fujii, Setsuro, et al.
Publicado: (1989)

Definitive Chemoradiotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil for Advanced Cervical Esophageal Cancer: A Medium-Term Outcome
por: Okamoto, Hiroshi, et al.
Publicado: (2022)

Serum Lactate Dehydrogenase Levels as a Predictive Marker of Oxaliplatin-Induced Hypersensitivity Reactions in Japanese Patients with Advanced Colorectal Cancer
por: Seki, Kyoko, et al.
Publicado: (2014)

Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5- fluorouracil in locally advanced nasopharyngeal carcinoma
por: Dechaphunkul, Tanadech, et al.
Publicado: (2011)

VEGF T-1498C polymorphism, a predictive marker of differentiation of colorectal adenocarcinomas in Japanese
por: Yamamori, Motohiro, et al.
Publicado: (2008)

Hyperammonemia Secondary to 5-Fluorouracil
por: Scott, Ashley, et al.
Publicado: (2023)

Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2(+) Breast Cancer Cells to 5-Fluorouracil
por: Yi, Jianing, et al.
Publicado: (2020)

Phase II Trial of 5‐Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer
por: Ueda, Hiroto, et al.
Publicado: (2018)

Risk Factors for Oxaliplatin-Induced Hypersensitivity Reactions in Japanese Patients with Advanced Colorectal Cancer
por: Seki, Kyoko, et al.
Publicado: (2011)

A Survey of the FAERS Database Concerning the Adverse Event Profiles of α1-Adrenoreceptor Blockers for Lower Urinary Tract Symptoms
por: Yoshimura, Koji, et al.
Publicado: (2013)

Definitive chemoradiotherapy with low-dose continuous 5-fluorouracil reduces hematological toxicity without compromising survival in esophageal squamous cell carcinoma patients
por: Saito, Hirotake, et al.
Publicado: (2017)

Bioavailability and feasibility of subcutaneous 5-fluorouracil.
por: Borner, M. M., et al.
Publicado: (1993)

5-fluorouracil and cardiotoxicity: a review
por: Sara, Jaskanwal D., et al.
Publicado: (2018)

5-Fluorouracil-induced vasospastic angina
por: Ayyildiz, Orhan, et al.
Publicado: (2005)

5-Fluorouracil Rechallenge After Cardiotoxicity
por: Desai, Aakash, et al.
Publicado: (2020)

Fluorouracil (5-FU)-induced Cardiomyopathy
por: Thalambedu, Nishanth, et al.
Publicado: (2019)

Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines
por: Shiga, Taro, et al.
Publicado: (2020)

5-Fluorouracil–Induced Coronary Vasospasm
por: Arya, Sumedha, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dt6ajl08qau7ltf4sqnqm2reeu